Kezar Life Sciences, Inc. (NASDAQ:KZR) Holdings Lifted by Acuitas Investments LLC

Acuitas Investments LLC raised its holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 42.8% in the second quarter, Holdings Channel.com reports. The fund owned 986,785 shares of the company’s stock after acquiring an additional 295,956 shares during the period. Acuitas Investments LLC’s holdings in Kezar Life Sciences were worth $592,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Ikarian Capital LLC raised its position in shares of Kezar Life Sciences by 1.8% during the first quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after purchasing an additional 15,601 shares during the period. Affinity Asset Advisors LLC acquired a new stake in Kezar Life Sciences during the 1st quarter worth about $1,588,000. Acadian Asset Management LLC lifted its stake in Kezar Life Sciences by 42.5% during the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after buying an additional 534,203 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kezar Life Sciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares during the period. Finally, Marquette Asset Management LLC purchased a new position in shares of Kezar Life Sciences in the first quarter worth approximately $114,000. 67.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Kezar Life Sciences in a research report on Wednesday, August 14th.

Kezar Life Sciences Stock Performance

Shares of KZR stock opened at $0.58 on Friday. The company has a market capitalization of $42.22 million, a price-to-earnings ratio of -0.41 and a beta of 0.20. Kezar Life Sciences, Inc. has a 1-year low of $0.54 and a 1-year high of $1.53. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $0.61 and its 200-day simple moving average is $0.74.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. On average, sell-side analysts predict that Kezar Life Sciences, Inc. will post -1.2 earnings per share for the current fiscal year.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.